Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
Sign Up to like & getrecommendations! Published in 2018 at "Inflammatory bowel diseases"
DOI: 10.1093/ibd/izy104
Abstract: Background Diarrhea and colitis are the second most common immune checkpoint inhibitor (ICPI)-induced adverse events. However, a comprehensive characterization of the endoscopic and histologic features of ICPI-induced diarrhea and colitis is lacking. Therefore, we aimed… read more here.
Keywords: colitis; diarrhea colitis; endoscopic histologic; histologic features ... See more keywords
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
Sign Up to like & getrecommendations! Published in 2018 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-018-0346-6
Abstract: BackgroundImmune checkpoint inhibitors (ICPIs) are gaining increasing popularity as an efficacious treatment for advanced malignancies. ICPI treatment can be complicated by diarrhea and colitis. Systemic steroids are the first line treatment. Infliximab is reserved for… read more here.
Keywords: treatment; diarrhea colitis; duration; induced diarrhea ... See more keywords
The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Current oncology"
DOI: 10.3747/co.27.6251
Abstract: Background Immune checkpoint inhibitors (icis), including inhibitors of PD-1, PD-L1, and ctla-4, are relatively novel therapies for lung cancer, although their use might be limited by gastrointestinal toxicity. The aim of the present study was… read more here.
Keywords: risk; diarrhea colitis; colitis; lung cancer ... See more keywords